Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Multidrug-resistant bacterial infections cause more than 19,000 excess deaths a year in Thailand alone, according to a study published today in eLife Sciences Publications. In a first for Thailand, the study systematically examined microbiology laboratory and hospital databases from nine public hospitals in Northeast Thailand and compared them to Thailand’s national death registry to estimate that 19,122 deaths in Thailand in 2010 were excess deaths caused by multidrug-resistant bacterial infections.

Scientist measuring the size of a bacteria colony in a petri dish © MORU. Photographer: Direk Limmathurotsakul

7 September 2016, Bangkok (Thailand) – Multidrug-resistant bacterial infections cause more than 19,000 excess deaths a year in Thailand alone, according to a study published today in eLife Sciences Publications.

In a first for Thailand, the study systematically examined microbiology laboratory and hospital databases from nine public hospitals in Northeast Thailand and compared them to Thailand’s national death registry to estimate that 19,122 deaths in Thailand in 2010 were excess deaths caused by multidrug-resistant bacterial infections.

Noting that Thailand’s death rate from multidrug-resistant bacterial infections was high given its smaller population relative to the United States and Europe, the study authors warned that similarly high death rates due to multidrug-resistant bacterial infection were likely to be found in other low and middle-income countries, such as China, India and Indonesia.

“Our study estimates that multidrug-resistant bacterial infections caused an excess of 19,122 deaths in Thailand in 2010. This is large compared to the 23,000 deaths a year estimated in the much more populous USA (316 million population in 2013) and the 25,000 deaths a year in the European Union (500 million population in 2007),” said study senior author Dr. Direk Limmathurotsakul, Head of Microbiology at MORU and Assistant Professor at Mahidol University (Thailand).

“We also show that the proportion of multidrug-resistant bacteria found in patients is increasing and that the burden of antibiotic resistance in Thailand is deteriorating over time,” said Dr. Limmathurotsakul.

“We expect to find similar high rates of multidrug resistant bacterial infections in other low and middle income countries, particularly where broad spectrum antibiotics such as ceftriaxone, ceftazidime and carbapenem are commonly available and used, such as in China, India and Indonesia,” said Dr. Limmathurotsakul.

Antimicrobial resistance is a growing global problem. In low and middle-income countries, bacteria resistant to many commonly used antibiotics are spreading, driven by rising incomes, greater use of affordable antibiotics by both humans and animals, a lack of control of antimicrobial use in hospitals and poor control of over-the-counter sales.

The study authors said that better national estimates on the epidemiology and burden of multidrug resistant bacterial infections could be improved by integrating information from readily available databases in Thailand and other low and middle-income countries.

“The impact of drug-resistant bacterial infections is already considerable – and getting worse. If it’s not to overwhelm Asia’s prosperity and the world’s economic, health and life expectancy gains, we need to take drug resistance seriously and invest heavily in its defeat – now, “ said study collaborator Dr. Nick Day, Director of MORU and Professor at the University of Oxford (UK).

“More systematic studies should be done in low and middle-income countries. We should focus on how to compare the antimicrobial resistance situation in countries where settings, resources for diagnostic tests and laboratory methodologies are different. Finally, we will need to identify where resources and attentions are most needed to effectively fight antimicrobial resistance,” said Prof Day.

Led by researchers at Ministry of Public Health and the Mahidol Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine and Siriraj Hospital, Mahidol University, in Thailand, and the University of Oxford and University of Cambridge in the United Kingdom, the study was funded by the Ministry of Public Health (Thailand) and the Wellcome Trust (UK).

“This study makes for grim reading, confirming that there were over 19,000 deaths in Thailand due to drug resistance in 2010, a figure which is likely to have risen since. It’s yet another warning to the global community that drug resistant infections are killing people now and we must not wait any longer to take action,” said Dr Jeremy Farrar, Director of the Wellcome Trust.

“Drug resistance is a global issue, which affects all of us whether we live in London or in Bangkok, and all countries need to be part of any solution. We cannot tackle drug resistant infections by isolating our actions to single countries or continents.  At the UN General Assembly later this month we urgently need governments to commit to strategies that combat drug resistance," said Dr Farrar.

Reference:

Lim et al. Epidemiology and Burden of Multidrug-resistant Bacterial Infection in a Developing Country. eLife 6 Sept 2016, http://dx.doi.org/10.7554/eLife.18082

For post publication access to abstract and full text:  http://dx.doi.org/10.7554/eLife.18082

Authors and contributors:

This work was conducted by: Cherry Lim, Emi Takahashi, Maliwan Hongsuwan, Visanu Thamlikitkul, Vanaporn Wuthiekanun, Soawapak Hinjoy, Nicholas Day, Sharon Peacock and Direk Limmathurotsakul.

Similar stories

MORU hepatitis work focusses on preventing mother-to-child transmission, high-at-risk populations, and remote communities

MORU Tropical Health Network researchers in Southeast Asia study various aspects of hepatitis B and C, infections that can lead to chronic liver diseases, and complications like liver cancer or cirrhosis. Researchers at MOCRU work on treatment for hepatitis C, a frequent opportunistic infection in HIV patients. MORU’s Clinical Pharmacology conducts two trials on possible treatments of hepatitis C. Hepatitis B is frequently transmitted from mother to child at birth, and SMRU researchers study mothers’ knowledge and behaviour, as well as prevention.

Incomplete reporting of COVID-19 disease severity criteria compromises meta-analysis

Patients affected by COVID-19 should be treated according to the severity of their disease. However, not all key national or international organisations define severity in the same way. This imprecision in severity assessment compromises the validity of some therapeutic recommendations. Using individual patient data would better guide and improve therapeutic recommendations for COVID-19.

Field evaluation of EasyScan GO: a digital malaria microscopy device

Microscopic examination of Giemsa-stained blood films is key to quantifying and detecting malaria parasites but there can be difficulties in ensuring both a high-quality manual reading and inter-reader reliability. The EasyScan GO was developed as a potential solution to this, a microscopy device using machine-learning-based image analysis for automated parasite detection and quantification.

Enhanced vaccination against Japanese encephalitis virus could reduce encephalitis prevalence by one third in SE Asia

Encephalitis is a worldwide public health issue, with a substantially high burden among children in Southeast Asia. A large study of the causes of childhood encephalitis in SE Asia suggests that enhanced and effective vaccination against the Japanese encephalitis virus alone could reduce encephalitis prevalence by one third.

Congratulations to Professor Sir David Warrell, appointed Knight Commander of the Order of St Michael and St George!

David Warrell, MORU founding director, has been appointed by the Queen ‘Knight Commander of the Order of St Michael and St George for services to global Health Research and Clinical Practice’. Please join us in congratulating Sir David on receiving this richly deserved high honour!

Laos’ first Pint of Science: warty newts, COVID, AI for Instagram, and more!

Organised by a grass-root community of thousands of scientists across the world, Pint of Science 2022 allows researchers in 25 countries and over 800 cities to share their latest findings with lay folk in interesting, informal settings. Lao PDR joined the global Pint of Science family on Monday 9 May, when the first-ever Pint of Science Laos kicked off!